Al Jazeera examines how “[a] series of public-health campaigns, including more aggressive screening, have been credited with a drop in tuberculosis [TB] cases in Kenya” in this video report. “The screening and treatment program, regarded as one of the best in the developing world, is credited with taking the rate of TB infections in the East African country from a high of 116,000 in 2006 to 106,000 last year,” but not without “an economic and political price,” the news service reports. “For TB screening and treatment programs to be effective, supply chains for drugs and equipment and proper training for staff and administrative back-up must be in place,” Al Jazeera reports (Greste, 1/9).
Discussing the recent reports of so-called “totally drug-resistant” tuberculosis (TDR-TB) in India, journalist John Donnelly in this GlobalPost “Global Voices” blog entry writes, “Overall, the world is treating drug-resistant TB extraordinarily poorly, and that creates more and more cases of resistant TB that aren’t being cured.” Donnelly describes his experience in Peru, where he and photographer Riccardo Venturi recently traveled at the invitation of the Japanese company Otsuka Pharmaceutical and “met with local scientists, doctors and patients to explore the scope of the struggle to fight drug-resistant TB” (1/19).
In a January 17 statement, India’s Ministry of Health and Family Welfare “dismissed reports that a form of incurable tuberculosis [TB] has arrived in the country,” saying “that a team of doctors sent by the ministry found that seven of the patients are responding to treatment” and the cases would be classified and managed as extremely drug-resistant TB (XDR-TB), Nature News Blog reports (Jayaraman, 1/19). “Earlier, doctors in Mumbai said 12 patients had a ‘totally drug resistant’ form of TB, and three had died,” according to BBC News. “A WHO official in India told the BBC that there is no recognized case of totally drug resistant TB anywhere in the world,” the news service writes (1/20).
Health officials from India and the WHO are scheduled to meet in Mumbai on Tuesday to discuss how to manage the cases of at least 12 patients infected with a highly drug-resistant tuberculosis (TB) strain, Bloomberg reports (Narayan, 1/17). “The ‘totally drug-resistant’ tuberculosis (TDR-TB) reportedly emerging in India is actually an advanced stage of drug-resistant TB, which researchers called totally drug-resistant for lack of a better term,” IRIN notes (1/17).
This post in the Foreign Policy Association blog discusses reports from earlier this month of “an emerging strain of ‘totally drug-resistant’ tuberculosis (TDR-TB)” in India, which the Indian government last week denied, “arguing that the 12 cases were in fact extensively drug resistant (XDR).” The blog states, “Whether or not it’s fair to use the TDR moniker, drug resistance is a serious, emerging issue that may very well define the next stage of global health,” concluding, “We are reaching a turning point, one at which some drug resistant pathogens are on the cusp of shifting from a handful of cases, an endemic, to a bigger, epidemic or even pandemic problem. Now is the time to initiate discussions on what the global community will do to stem drug resistance” (Robinson, 1/21).
A funding shortfall led the Global Fund to Fight AIDS, Tuberculosis and Malaria to announce in November that “it won’t make any grants to fund programs for at least two years,” a Deseret News editorial notes and calls on the U.S. to take a leadership position in saving the fund. The editorial states, “Few worldwide initiatives have the success record of the Global Fund …, but those breakthroughs may not have much chance to save many lives,” and notes that the non-profit lobbying group “Results is calling for the Obama administration to assemble an emergency meeting of donor nations this spring to find ways to ensure that the fund and its programs are able to continue and to provide new medicines where they are needed most.”
In this post in Global Health Frontline News’ “Notes From the Field” blog, Kevin Cain, chief of the tuberculosis (TB) branch for a research and public health collaboration between the Kenya Medical Research Institute (KEMRI) and the CDC in Kisumu, Kenya, reports on TB research underway as part of the collaboration. Cain highlights several current research initiatives in Kisumu and concludes, “The world cannot afford another phase of neglect. We know by partnering with governments as well as affected communities in innovative ways more progress can be made improving programs and the tools available for diagnosing, treating, and preventing TB, and lives will be saved” (1/20).
In this post in the PLoS “Speaking of Medicine” blog, guest blogger Christian Lienhardt, senior scientific adviser at the Stop TB Partnership and WHO, “discusses the International Roadmap for Tuberculosis (TB) Research, a framework outlining priority areas for investment in TB research.” He writes, “The tools available for TB control are old, lack effectiveness, and are not readily accessible in many settings,” adding, “Fortunately there is hope, thanks to notable progress in the development of new tools for TB control over the last decade,” such as “the recent introduction of Xpert MTB/RIF — a DNA-based molecular assay that can diagnose TB and the presence of rifampicin-resistance in 100 minutes” (1/26).
“One in 10 cases of tuberculosis in China cannot be treated by the most commonly-used drugs, driven by a lack of testing and misuse of medicine, according to a national survey that showed for the first time the size of the drug-resistant epidemic,” the Associated Press reports (Wong, 6/7). “‘In 2007, one third of the patients with new cases of tuberculosis and one half of the patients with previously treated tuberculosis had drug-resistant disease,’ said the study in the New England Journal of Medicine,” Agence France-Presse reports, adding, “Even more, the prevalence of multi-drug resistant [tuberculosis (MDR-TB)] in new cases (5.7 percent) was nearly twice the global average, said the study” (6/6).
“Researchers who tested a novel type of antibiotic against multi-drug-resistant tuberculosis [MDR-TB] are reporting that nearly half of patients who got the new drug cleared the bacteria from their lung fluid in two months,” according to a study published Thursday in the New England Journal of Medicine, Reuters reports. Japanese pharmaceutical company Otsuka developed the experimental drug, delamanid, and “also designed and financed the clinical trial, which took place in 17 medical centers across nine countries,” the news service writes (Emery, 6/6).